Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
2003 1
2018 1
2020 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year
Filters applied: . Clear all
Page 1
Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors.
Decary S, Berne PF, Nicolazzi C, Lefebvre AM, Dabdoubi T, Cameron B, Rival P, Devaud C, Prades C, Bouchard H, Cassé A, Henry C, Amara C, Brillac C, Ferrari P, Maçon L, Lacoste E, Combeau C, Beys E, Naimi S, García-Echeverría C, Mayaux JF, Blanc V. Decary S, et al. Among authors: casse a. Clin Cancer Res. 2020 Dec 15;26(24):6589-6599. doi: 10.1158/1078-0432.CCR-19-4051. Epub 2020 Oct 12. Clin Cancer Res. 2020. PMID: 33046521 Free article.
Colibactin-positive Escherichia coli induce a procarcinogenic immune environment leading to immunotherapy resistance in colorectal cancer.
Lopès A, Billard E, Casse AH, Villéger R, Veziant J, Roche G, Carrier G, Sauvanet P, Briat A, Pagès F, Naimi S, Pezet D, Barnich N, Dumas B, Bonnet M. Lopès A, et al. Among authors: casse ah. Int J Cancer. 2020 Jun 1;146(11):3147-3159. doi: 10.1002/ijc.32920. Epub 2020 Mar 10. Int J Cancer. 2020. PMID: 32037530 Free article.